The Japanese government has requested that medical institutions within the country use diabetes medications, including Mountjaro, appropriately. This directive comes as demand for such drugs increases, potentially straining supply and resources. The request emphasizes the need for judicious prescribing practices to ensure equitable access for patients who require these treatments. While not a restriction, the government aims to prevent unnecessary prescriptions and maintain a stable supply of Mountjaro and similar medications. This move signals a proactive approach to managing the growing prevalence of diabetes and the associated pharmaceutical needs within Japan. Further details regarding specific guidelines for “appropriate use” have not yet been released, but officials indicate they will be forthcoming.